Coronary Artery Disease Clinical Trial
Official title:
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in Comparison With the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
Verified date | April 2024 |
Source | Medtronic Vascular |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary stent system in the treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) in China.
Status | Active, not recruiting |
Enrollment | 550 |
Est. completion date | September 19, 2025 |
Est. primary completion date | February 12, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - The subject is an acceptable candidate for treatment with a drug-eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, the IB of Resolute Onyx stent, and the IFU of Resolute Integrity stent - The subject requires treatment of up to 3 target lesions in up to 2 separate target vessels [2 target lesions in 1 vessel (including its side branches) and 1 target lesion in a separate vessel(including its side branches)] amenable to treatment with stents with diameter from 2.25 mm to 4.0 mm Key Exclusion Criteria: - Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, P2Y12 inhibitors, mTOR inhibiting drugs such as zotarolimus, Biolimus A9 (or its derivatives), cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be adequately pre-medicated - PCI of the target vessel within 9 months prior to the procedure - Active bleeding - Subjects with a life expectancy of less than 12 months - Participation in another clinical study - Pregnant, or lactating women |
Country | Name | City | State |
---|---|---|---|
China | Fuwai Hospital, Chinese Academy of Medical Science | Beijing | |
China | Shengjing Hospital of China Medical University | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
Medtronic Vascular |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | In-stent Late lumen loss measured by quantitative coronary angiography (QCA) | Late lumen loss measured by quantitative coronary angiography (QCA) | 9 months | |
Secondary | Device Success | Definition 1: The attainment of <50% residual stenosis of the target lesion using only the assigned device.
Definition 2: The attainment of < 30% residual stenosis by QCA (or < 20% by visual assessment) AND a TIMI flow 3 after the procedure, using the assigned device only. These measurements will be made by the independent angiographic core laboratory. |
at the end of the index procedure or during hospital stay: estimated 7 days | |
Secondary | Lesion Success | Definition 1: The attainment of <50% residual stenosis of the target lesion using any percutaneous method.
Definition 2: The attainment of < 30% residual stenosis by QCA (or < 20% by visual assessment) AND a TIMI flow 3 after the procedure, using the assigned device only. These measurements will be made by the independent angiographic core laboratory. |
at the end of the index procedure or during hospital stay: estimated 7 days | |
Secondary | Procedure Success | Definition 1: The attainment of <50% residual stenosis of the target lesion and no in-hospital MACE.
Definition 2: The attainment of < 30% residual stenosis by QCA (or < 20% by visual assessment) AND a TIMI flow 3 after the procedure, using the assigned device only. These measurements will be made by the independent angiographic core laboratory. |
at the end of the index procedure or during hospital stay: estimated 7 days | |
Secondary | Major Adverse Cardiac Events (MACE) | Defined as composite of death, myocardial infarction (Q wave and non-Q wave), emergent coronary bypass surgery, or clinically-driven repeat target lesion revascularization by percutaneous or surgical methods | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | Death (Cardiac and Non-cardiac) | All deaths | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | Myocardial infarction (all MI, and Target Vessel Myocardial Infarction (TVMI)) | All myocardial infarction data will be reported per Medtronic historical protocol definitions. | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | All revascularizations | Target Legion Revascularization (TLR), Target Vessel Revascularization (TVR) and Non-TVR | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | Target Vessel Failure (TVF) | TVF | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | Target Lesion Failure (TLF) | TLF | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | Stent Thrombosis (ST) | ST | 30 day, 6 months, 9 months, 1 year, 2 years,3 years, 4 years, 5 years | |
Secondary | In-stent and in-segment percent diameter stenosis (%DS) | Angiographic measures: In-stent and in-segment percent diameter stenosis (%DS) | 9 months | |
Secondary | In-stent and in-segment binary restenosis rate | Angiographic measures:In-stent and in-segment binary restenosis rate | 9 months | |
Secondary | In-stent and in-segment minimal luminal diameter (MLD) | Angiographic measures:In-stent and in-segment minimal luminal diameter (MLD) | 9 months | |
Secondary | In-segment late luminal loss | Angiographic measures: In-segment late luminal loss | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |